Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey

Diabetes and Metabolism

Volumn 30, Issue 4, 2004, Pages 327-333

  Damci, T ^a,e   Kultursay, H ^b   Oguz, A ^c   Pehlivanoglu, S ^a   Tokgozoglu, L ^d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c SSK Goztepe Hospital   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

^e Hacettepe University Medical Faculty ^*  (Turkey)

Author keywords

Cardiovascular risk factors; Diabetes; Drug treatment; Turkey

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIABETES MELLITUS; DISEASE DURATION; DRUG THERAPY; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MICROALBUMINURIA; MONOTHERAPY; PRESCRIPTION; PROTECTION; RENAL PROTECTION; RISK FACTOR; SUBOPTIMAL DRUG THERAPY; TURKEY (REPUBLIC);

EID: 4644290758     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70124-6     Document Type: Article

References (34)

1. Satman I, Yilmaz T, Sengul A, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care, 2002, 25, 1551-6.
2. King H, Aubert RE, Herman WH. Global burden of diabetes. 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care, 1998, 21, 1414-31.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-44.
4. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000, 23, 962-68.
5. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 1998, 21, 1138-45.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med, 1998, 339, 229-34.
7. Hannson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1998, 351, 1755-62.
8. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 1997, 20, 614-20.
9. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation, 1998, 98(23), 2513-19.
10. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC IV). Arc Int Med, 1997, 157, 2413-46.
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-97.
12. Heart Outcomes Prevention Evaluation Study Investigators. Efects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000, 355, 253-9.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med, 2001, 345, 851-60.
14. Brenner BM, Cooper ME, de Zeeuw O, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med, 2001, 345, 861-69.
15. American Diabetes Association. Treatment of Hypertension in Adults with Diabetes (Position Statement). Diabetes Care, 2003, 26, Suppl 1, S80-S82.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
17. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 1999, 354, 617-21.
18. ETDRS investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA, 1992, 268, 1292-300.
19. American Diabetes Association. Aspirin therapy in diabetes (Position Statement). Diabetes Care, 2003, 26, S87-S8.
20. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med, 2003, 348, 383-93.
21. Porsch-Oezcueruemez M, Bilgin Y, Wollny M, et al. Prevalence of risk factors of coronary heart disease in Turks living in Germany: The Giessen Study. Atherosclerosis, 1999, 144, 185-98.
22. Malmberg K, for the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ, 1997, 314, 1512-5.
23. American Diabetes Association. Standards of Medical Care for Patients with Diabetes Mellitus (Position Statement). Diabetes Care, 2003, 26, S33-S50.
24. Skyler JS. Insulin therapy in Type 2 Diabetes Mellitus. In Current Management of Diabetes Mellitus ed. DeFronzo RA Mosby-Year Book, Inc 1998, 108-16.
25. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Eng J Med, 1993, 329, 977-86.
26. Feiglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care, 1999, 22, C61-C64.
27. Pickup J. The pursuit of perfect control in diabetes. Br Med J, 1988, 929-31.
28. Wingard DL, Barett-Connor E. Heart disease and diabetes. In Diabetes in America. Washington DC, US Govt. Printing Office, 1995, 429-48.
29. UK Prospective Diabetes Study Group: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-13.
30. Gottlieb SS, Mc Carter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Eng J Med, 1998, 339, 489-97.
31. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet, 2002, 360, 7-22.
32. Winocour PH. Effective diabetes care: a need for realistic targets. Lancet, 2002, 324, 1577-80.
33. Mahley RW, Paloglu KE, Atak Z, et al Turkish Heart Study: lipids, lipoproteins and apolipoproteins. J Lipid Res, 1995, 36, 839-59.
34. Rubins HB, Rubins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng J Med, 1999, 341, 410-8.